Latest Biota Holdings Limited Stories
Biota Holdings Limited (ASX: BTA) today announced that its second generation, influenza treatment, CS-8958, has successfully completed its initial Phase II clinical evaluation, showing favourable outcomes against all measured endpoints.
Biota Holdings Limited (ASX: BTA) today announced it had concluded its litigation against GlaxoSmithKline (GSK). The announcement followed formal mediation between by the parties ordered by the Victorian Supreme Court.
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.